xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05983328</url>
    </required_header>
    <id_info>
      <org_study_id>Oral HUYPS-1-001</org_study_id>
      <nct_id>NCT05983328</nct_id>
    </id_info>
    <brief_title>Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers</brief_title>
    <official_title>A Randomized, Open-label, Single Dose, Crossover Design Phase I Study to Evaluate Tolerability, Safety and Pharmacokinetics of HUYPS-1 in Healthy Volunteers</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Sinew Pharma Inc.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Sinew Pharma Inc.</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study&#xD;
        period.&#xD;
  &#xD;
        Period: 24 hours post dose in each period. Each subject will complete two study periods.&#xD;
  &#xD;
        Washout Period: At least one week after dosing of the previous period.&#xD;
  &#xD;
        Confinement: From at least 10 hours prior to dosing until at least 12 hours post-dose, for a&#xD;
        total of at least 22 hours for each study period.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This study is a single center and open-label design to evaluate tolerability, safety and&#xD;
        pharmacokinetic properties of HUYPS-1 after single oral administration in healthy subjects&#xD;
        under fasting conditions. A total of 14 eligible subjects are expected to be enrolled to&#xD;
        ensure 12 evaluable subjects. The study will be completed when there are at least 12&#xD;
        evaluable subjects. The evaluable subjects are those who have completed both periods.&#xD;
        Eligible subjects will be randomly assigned to either of the two treatment sequences.&#xD;
  &#xD;
        The study design in a 2-sequence, 2-period crossover design. There is at least 7-day washout&#xD;
        time between periods. The formulation of HUYPS-1 for oral administration contains 100 mg&#xD;
        mannitol and 100 mg sucralose per tablet will be given by one or nine tablets per person of&#xD;
        each period. Mannitol and sucralose are both commonly used excipients approved by WHO. These&#xD;
        excipients are included in the FDA Inactive Ingredients Guide, GRAS (generally recognized as&#xD;
        safe) and commonly used pharmaceutical excipients, therefore the oral doses of these&#xD;
        excipients can be regarded as extremely safe in this study.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">May 10, 2016</start_date>
    <completion_date type="Actual">February 9, 2018</completion_date>
    <primary_completion_date type="Actual">May 26, 2016</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs):</measure>
      <time_frame>24 hours</time_frame>
      <description>An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of maximum concentration of HUYPS-1 (Cmax)</measure>
      <time_frame>24 hours</time_frame>
      <description>Concentrations of HUYPS-1 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  Cmax</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of time of occurrence for maximum (peak) HUYPS-1 concentration (Tmax)</measure>
      <time_frame>24 hours</time_frame>
      <description>Concentrations of HUYPS-1 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  Tmax</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of area under curve (AUC0-t) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>Concentrations of HUYPS-1 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  AUC0-t</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of area under curve infinity (AUCINF) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  AUCINF</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of overall HUYPS-1 elimination rate constant (k)</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  k</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of elimination half-life (T1/2) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  T1/2</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of mean residence time (MRT) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  MRT</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of clearance (CL/F) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  CL/F</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of apparent volume (Vd/F) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  Vd/F</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of area under moment curve (AUMC(0-t)) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  AUMC(0-t)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetic profile of area under moment curve infinity (AUMCINF) for HUYPS-1</measure>
      <time_frame>24 hours</time_frame>
      <description>LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.&#xD;
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:&#xD;
  AUMCINF</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Actual">14</enrollment>
    <condition>Nonalcoholic Steatohepatitis</condition>
    <arm_group>
      <arm_group_label>Healthy Volunteers dose 1</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 1 tablet oral administration in healthy subjects</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Healthy Volunteer dose 2</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 9 tablets oral administration in healthy subjects</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>HUYPS-1 one tablet</intervention_name>
      <description>After 7-day washout time, subjects will receive HUYPS-1 1 tablet.</description>
      <arm_group_label>Healthy Volunteers dose 1</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>HUYPS-1 nine tablets</intervention_name>
      <description>After 7-day washout time, subjects will receive HUYPS-1 9 tablets.</description>
      <arm_group_label>Healthy Volunteer dose 2</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Normal healthy adult subjects between 20-50 years of age.&#xD;
  &#xD;
            2. Acceptable medical history and physical examination including:&#xD;
  &#xD;
            3. Acceptable clinical laboratory determinations without significant deviation from&#xD;
               normal values within two months prior to Period I dosing, which includes AST (SGOT),&#xD;
               ALT (SGPT), r-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric&#xD;
               acid, creatinine, total cholesterol, triglyceride (TG) and galactose single point&#xD;
               (GSP).&#xD;
  &#xD;
            4. Acceptable hematology within two months prior to the study, which includes hemoglobin,&#xD;
               hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white&#xD;
               blood cells and platelets.&#xD;
  &#xD;
            5. Acceptable urinalysis within two months prior to the study, which includes pH, blood,&#xD;
               glucose and protein.&#xD;
  &#xD;
            6. Signed the written informed consent to participate in this study.&#xD;
  &#xD;
            7. Acceptable body mass index (BMI): 18.5 &lt; BMI &lt; 25 kg/m2&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Recent history of drug or alcohol addiction or abuse within the past year.&#xD;
  &#xD;
            2. A clinically significant disorder involving the cardiovascular, respiratory, renal,&#xD;
               gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or&#xD;
               psychiatric disease (as determined by the clinical investigator).&#xD;
  &#xD;
            3. History of allergic response(s) to mannitol, sucralose or related drugs.&#xD;
  &#xD;
            4. History of clinically significant allergies including drug allergies or allergic&#xD;
               bronchial asthma.&#xD;
  &#xD;
            5. Evidence of chronic or acute infectious diseases.&#xD;
  &#xD;
            6. Any clinically significant illness or surgery during the one month prior to Period I&#xD;
               dosing (as determined by the clinical investigator).&#xD;
  &#xD;
            7. Taking any drug known to induce or inhibit hepatic drug metabolism within one month&#xD;
               prior to the beginning of the study.&#xD;
  &#xD;
            8. Receiving any investigational drug within one month prior to Period I dosing.&#xD;
  &#xD;
            9. Taking any prescription medication or any nonprescription medication within two weeks&#xD;
               prior to Period I doing.&#xD;
  &#xD;
           10. Donating greater than 150 mL of blood within two months prior to Period I dosing or&#xD;
               donating plasma (e.g. plasmapheresis) within two weeks prior to Period I dosing. All&#xD;
               subjects will be advised not to donate blood for four weeks after completing the&#xD;
               study.&#xD;
  &#xD;
           11. Consumption of caffeine, xanthine-containing products (i.e. coffee, tea,&#xD;
               caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol, smoke or use&#xD;
               tobacco products within 48 hours prior to days on which dosing is scheduled and during&#xD;
               the periods when blood samples are being collected.&#xD;
  &#xD;
           12. Any other medical reason as determined by the clinical investigator.&#xD;
  &#xD;
           13. Subject is pregnant or breastfeeding.&#xD;
  &#xD;
           14. Women of childbearing potential disagree to use an acceptable method of contraception&#xD;
               (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the&#xD;
               study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>20 Years</minimum_age>
      <maximum_age>50 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <location>
      <facility>
        <name>Tri-Service General Hospital</name>
        <address>
          <city>Taipei</city>
          <zip>114</zip>
          <country>Taiwan</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Taiwan</country>
    </location_countries>
    <verification_date>April 2023</verification_date>
    <study_first_submitted>March 5, 2018</study_first_submitted>
    <study_first_submitted_qc>August 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 9, 2023</study_first_posted>
    <last_update_submitted>August 1, 2023</last_update_submitted>
    <last_update_submitted_qc>August 1, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 9, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Fatty Liver</mesh_term>
      <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05983328
  org study id: Oral HUYPS-1-001
  nct id: NCT05983328
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study
        period.
  
        Period: 24 hours post dose in each period. Each subject will complete two study periods.
  
        Washout Period: At least one week after dosing of the previous period.
  
        Confinement: From at least 10 hours prior to dosing until at least 12 hours post-dose, for a
        total of at least 22 hours for each study period.
  This study is a single center and open-label design to evaluate tolerability, safety and
        pharmacokinetic properties of HUYPS-1 after single oral administration in healthy subjects
        under fasting conditions. A total of 14 eligible subjects are expected to be enrolled to
        ensure 12 evaluable subjects. The study will be completed when there are at least 12
        evaluable subjects. The evaluable subjects are those who have completed both periods.
        Eligible subjects will be randomly assigned to either of the two treatment sequences.
  
        The study design in a 2-sequence, 2-period crossover design. There is at least 7-day washout
        time between periods. The formulation of HUYPS-1 for oral administration contains 100 mg
        mannitol and 100 mg sucralose per tablet will be given by one or nine tablets per person of
        each period. Mannitol and sucralose are both commonly used excipients approved by WHO. These
        excipients are included in the FDA Inactive Ingredients Guide, GRAS (generally recognized as
        safe) and commonly used pharmaceutical excipients, therefore the oral doses of these
        excipients can be regarded as extremely safe in this study.
  allocation: Randomized
  intervention model: Crossover Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs):
  time frame: 24 hours
  description: An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
  measure: Pharmacokinetic profile of maximum concentration of HUYPS-1 (Cmax)
  time frame: 24 hours
  description: Concentrations of HUYPS-1 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  Cmax
  measure: Pharmacokinetic profile of time of occurrence for maximum (peak) HUYPS-1 concentration (Tmax)
  time frame: 24 hours
  description: Concentrations of HUYPS-1 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  Tmax
  measure: Pharmacokinetic profile of area under curve (AUC0-t) for HUYPS-1
  time frame: 24 hours
  description: Concentrations of HUYPS-1 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  AUC0-t
  measure: Pharmacokinetic profile of area under curve infinity (AUCINF) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  AUCINF
  measure: Pharmacokinetic profile of overall HUYPS-1 elimination rate constant (k)
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  k
  measure: Pharmacokinetic profile of elimination half-life (T1/2) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  T1/2
  measure: Pharmacokinetic profile of mean residence time (MRT) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  MRT
  measure: Pharmacokinetic profile of clearance (CL/F) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  CL/F
  measure: Pharmacokinetic profile of apparent volume (Vd/F) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  Vd/F
  measure: Pharmacokinetic profile of area under moment curve (AUMC(0-t)) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  AUMC(0-t)
  measure: Pharmacokinetic profile of area under moment curve infinity (AUMCINF) for HUYPS-1
  time frame: 24 hours
  description: LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of HUYPS-1 and its metabolites in health subjects oral HUYPS-1 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method.
  The following parameters of HUYPS-1 will be determined using WINNONLINTM:
  AUMCINF
  arm group label: Healthy Volunteers dose 1
  arm group type: Experimental
  description: Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 1 tablet oral administration in healthy subjects
  arm group label: Healthy Volunteer dose 2
  arm group type: Experimental
  description: Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 9 tablets oral administration in healthy subjects
  intervention type: Drug
  intervention name: HUYPS-1 one tablet
  description: After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
  arm group label: Healthy Volunteers dose 1
  intervention type: Drug
  intervention name: HUYPS-1 nine tablets
  description: After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
  arm group label: Healthy Volunteer dose 2
  criteria: 
  gender: All
  minimum age: 20 Years
  maximum age: 50 Years
  healthy volunteers: Accepts Healthy Volunteers
  facility: 
  country: Taiwan
  responsible party type: Sponsor
  mesh term: Fatty Liver
  mesh term: Non-alcoholic Fatty Liver Disease
  sharing ipd: No